Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nivolumab + nab-paclitaxel
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Nivolumab + nab-paclitaxel is a combination therapy consisting of two distinct agents used primarily in oncology. Nivolumab is a fully human IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on T cells, blocking its interaction with PD-L1 and PD-L2, thereby enhancing anti-tumor immune responses. Nab-paclitaxel (nanoparticle albumin-bound paclitaxel) is a formulation of the cytotoxic agent paclitaxel bound to albumin nanoparticles, which facilitates enhanced delivery to tumor tissue via albumin-mediated transport mechanisms and improves solubility compared to conventional paclitaxel. This combination has been investigated for use in several cancers, including muscle-invasive bladder cancer and pancreatic cancer, where it may offer synergistic effects by combining immune checkpoint inhibition with cytotoxic chemotherapy[2][3][5][6].
- Other names
- nivolumab + albumin-bound paclitaxelnivolumab + nanoparticle albumin-bound paclitaxel
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nivolumab + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nivolumab + nab-paclitaxel.